Glucosamine as a pain-modifying drug in osteorthritis: What's new in 2006;Activité antalgique de la glucosamine dans l'arthrose: Quoi de neuf en 2006?

Revue Medicale de Liege

Volumn 61, Issue 3, 2006, Pages 169-172

  Reginster, Jean Yves ^a,b   Richy, F ^b   Bruyere, O ^b  

^a Service de Santé Publique Epidémiologie et Economie de la Santé   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chondroitin; Glucosamine; Osteoarthritis; Symptoms; Treatment

Indexed keywords

CHONDROITIN; GLUCOSAMINE;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; EUROPE; HUMAN; KNEE OSTEOARTHRITIS; MEDICAL SOCIETY; UNITED STATES;

ARTHRALGIA; CHONDROITIN; CLINICAL TRIALS; DRUG COMBINATIONS; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS;

EID: 33645983205     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Reginster JY, Deroisy R, Rovati LC, et al.- Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001, 357, 251-256.
2. Pavelka K, Gatterova J, Olejarova M, et al.- Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med, 2002, 162, 2113-2223.
3. Herrero-Beaumont G, Roman JA, Trabado MC, et al.- Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms vs placebo and acetaminophen: results from the Glucosamine. Unum in Die Efficacy (GUIDE) trial. (abstract) Arthritis Rheum, 2005, 52, 460.
4. Clegg DO, Reda DJ, Harris CL, et al.- Glucosamine, chondroitine sulphate, and the two in combination for painful knee osteoarthritis. N Engl J Med, 2006, 354, 795-808.
5. Hochberg MC.- Nutritional supplements for knee osteoarthritis-still no resolution. N Engl J Med, 2006, 354, 858-860.
6. Jordan KM, Arden NK, Doherty M, et al.- Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62, 1145-1155.
7. Russell AS, Aghazadeh-Habashi A, Jamali F.- Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol, 2002, 29, 2407-2409.
8. Hoffer LJ, Kaplan LN, Hamadeh MJ, et al.- Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism, 2001, 50, 767-770.
9. Cordobal F, Nimni ME.- Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulphur amino acids. Osteoathritis Cartilage, 2003, 11, 228-230.
10. Towheed TE, Maxwell L, Anastassiades TP, et al.- Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev, 2005, 2, CD002946.
11. Mroz PJ, Silbert JE.- Use of 3 H-glucosamine and 35 S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum, 2004, 50, 3574-3579.
12. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al.- Glucosamine inhibits IL-1β-induced NFkB activation in human osteoarthritis chondrocytes. Osteoarthritis Cartilage, 2003, 11, 290-298.
13. Piepoli T, Zanelli T, Letari O, et al.- Glucosamine sulphate inhibits IL-1-stimulated gene expression at concentrations found in human plasma after oral intake. Osteoarthritis Cartilage, 2005, 13, 304.
14. Persiani S, Rotini R, Trisolino G, et al.- Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients. Arthritis Rheum, 2005, 9, 1342.